VEDBAEK, Denmark, Sept. 15, 2009 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ) today announced the successful completion of several key milestones in a custom-designed RNAi project for Tacere Therapeutics. This project resulted from a collaboration between Tacere and Pfizer Inc. to develop and commercialize the TT-033 family of compounds to provide a potential single-administration treatment for the Hepatitis C virus (HCV).
